Uremic toxins;Les toxines urémiques

Nephrologie

Volumn 24, Issue 7, 2003, Pages 373-376

  Vanholder, Raymund ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Cardio vascular complications; Inflammation; Uremic toxins

Indexed keywords

BIOCHEMICAL MARKER; UREA; UREMIC TOXIN; WATER;

CARDIOVASCULAR DISEASE; CONFERENCE PAPER; HUMAN; INFLAMMATION; KIDNEY FAILURE; MOLECULE; PROTEIN BINDING; SOLUBILITY; SOLUTE; TOXICITY; URINARY EXCRETION; URINE RETENTION;

CARDIOVASCULAR DISEASES; HUMANS; INFLAMMATION; MOLECULAR WEIGHT; PROTEIN BINDING; RENAL DIALYSIS; TOXINS, BIOLOGICAL; UREMIA;

EID: 0344876615     PISSN: 02504960     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (13)

1. Vanholder R, Argiles A, Baurmeister U, Brunet P, Clark W, Cohen G, De Deyn PP, Deppisch R, Descamps-Latscha B, Henle T, Jorres A, Massy ZA, Rodriguez M, Stegmayr B, Stenvinkel P, Wratten ML. Uremic toxicity: Present state of the art. Int J Artif Organs 2001; 24: 695-725.
2. Vanholder R, De Smet R. Pathophysiologic effects of uremic retention solutes. J Am Soc Nephrol 1999; 10:1815-23.
3. Lim J, Gasson C, Kaji DM. Urea inhibits NaK2CI cotransport in human erythrocytes. J Clin Invest 1995; 96: 2126-32.
4. Johnson WJ, Hagge WW, Wagoner RD, Dinapoli RP, Rosevear JW. Effects of urea loading in patients with far-advanced renal failure. Mayo Clin Proc 1972; 47: 21-9.
5. Vanholder RC, De Smet RV, Ringoir SM. Assessment of urea and other uremic markers for quantification of dialysis efficacy. Clin Chem 1992; 38: 1429-36.
6. Eknoyan G, Beck GJ, Cheung AK, Daugirdas JT, Greene T, Kusek JW, Allon M, Bailey J, Delmez JA, Depner TA, Dwyer JT, Levey AS, Levin NW, Milford E, Ornt DB, Rocco MV, Schulman G, Schwab SJ, Teehan BP, Toto R. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med 2002; 347: 2010-9.
7. Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: A national study. Am J Kidney Dis 1998; 31: 607-17.
8. Vanholder R, De Smet R, Waterloos MA, Van Landschoot N, Vogeleere P, Hoste E, Ringoir S. Mechanisms of uremic inhibition of phagocyte reactive species production: Characterization of the role of p-cresol. Kidney Int 1995; 47: 510-7.
9. Niwa T, Sato M, Katsuzaki T, Tomoo T, Miyazaki T, Tatemichi N, Takei Y, Kondo T. Amyloid beta 2-microglobulin is modified with N epsilon-(carboxymethyl)lysine in dialysis-related amyloidosis. Kidney Int 1996; 50: 1303-9.
10. Locatelli F, Mastrangelo F, Redaelli B, Ronco C, Marcelli D, La Greca G, Orlandini G, Effects of different membranes and dialysis technologies on patient treatment tolerance and nutritional parameters. The Italian Cooperative Dialysis Study Group. Kidney Int 1996; 50: 1293-302.
11. Koda Y, Nishi S, Miyazaki S, Haginoshita S, Sakurabayashi T, Suzuki M, et al. Switch from conventional to high-flux membrane reduces the risk of carpal tunnel syndrome and mortality of hemodialysis patients. Kidney Int 1997; 52: 1096-101.
12. Stenvinkel P, Lindholm B, Lonnqvist F, Katzarski K, Heimburger O. Increases in serum leptin levels during peritoneal dialysis are associated with inflammation and a decrease in lean body mass. J Am Soc Nephrol 2000; 11: 1303-9.
13. Witko-Sarsat V, Friedlander M, Nguyen KT, Capeiliere-Blandin C, Nguyen AT, Canteloup S, Dayan JM, Jungers P, Drueke T, Descamps-Latscha B. Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure. J Immunol 1998; 161: 2524-32.